Back to Search
Start Over
A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases.
- Source :
-
Arthritis research & therapy [Arthritis Res Ther] 2024 Sep 04; Vol. 26 (1), pp. 155. Date of Electronic Publication: 2024 Sep 04. - Publication Year :
- 2024
-
Abstract
- Objectives: To analyse clinical outcomes of a non-medical switch from originator adalimumab (ADA) to its ABP501 biosimilar (ABP) over 6 months in patients with inflammatory rheumatic musculoskeletal diseases (RMD) in relation to comorbidity as a risk factor for therapy discontinuation.<br />Methods: RMD patients switching from originator ADA to ABP were identified from a large routine database from October 2018 onwards. Documented clinical data at the time of non-medical switching (baseline), and at 3 and 6 months were collected. Comorbidities were represented by the Charlson Comorbidity Index (CCI) at baseline and patients were categorized based on CCI > 0. Differences in the ABP retention rate over 6 months between patients with CCI = 0 and patients with CCI > 0 were analysed using Bayesian exponential regression.<br />Results: A total of 111 patients with axial spondyloarthritis (n = 68), rheumatoid arthritis (n = 23) and psoriatic arthritis (n = 15), were identified, 74.8% of whom had continued treatment with ABP after 6 months, while a smaller proportion had either switched to another ADA biosimilar (10.8%), switched back to originator ADA (7.2%), switched to a different biologic (3.6%), or dropped out (3.6%). At baseline, a CCI > 0 was found in 38% of patients. Cardiovascular comorbidities (40%) were most prevalent followed by diseases of the skin (33%), the gastrointestinal tract (20%) and the eye (20%). ABP treatment was continued after 6 months in 74% of patients with CCI = 0 and in 76% with CCI > 0. Bayesian analysis showed only a small difference (months) in the APB continuation rate between groups (estimate 0.0012, 95% credible interval (CrI) -0.0337 to 0.0361). Adjusting for age, sex, and disease subtype revealed somewhat shorter retention rates for patients with CCI > 0, but the distribution of the difference included 0 (estimate -0.0689, 95% CrI -0.2246 to 0.0234).<br />Conclusion: In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6 months between comorbidity groups.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Female
Male
Middle Aged
Adult
Drug Substitution statistics & numerical data
Rheumatic Diseases drug therapy
Rheumatic Diseases epidemiology
Aged
Musculoskeletal Diseases epidemiology
Musculoskeletal Diseases drug therapy
Treatment Outcome
Bayes Theorem
Biosimilar Pharmaceuticals therapeutic use
Antirheumatic Agents therapeutic use
Comorbidity
Adalimumab therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1478-6362
- Volume :
- 26
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Arthritis research & therapy
- Publication Type :
- Academic Journal
- Accession number :
- 39232829
- Full Text :
- https://doi.org/10.1186/s13075-024-03386-7